Complications and outcomes
| All patients (n = 104) | Early group (n = 20) | Late group (n = 84) | p Value | |
|---|---|---|---|---|
| Embolic events | 35 (33%) | 6 (30%) | 29 (35%) | 0.67 |
| Cerebral haemorrhage | 5 (5%) | 2 (10%) | 3 (4%) | 0.51 |
| Severe heart failure | 32 (31%) | 7 (35%) | 25 (30%) | 0.65 |
| High level conduction abnormality | 6 (6%) | 1 (5%) | 5 (6%) | 1 |
| Surgery (active phase <30 days) | 51 (49%) | 16 (80%) | 35 (41%) | 0.001 |
| In-hospital mortality | 22 (21%) | 6 (30%) | 16 (19%) | 0.43 |
| After surgery in active phase | 9 (17%) | 5 (31%) | 4 (11%) | 0.16 |
| After medical treatment in active phase | 13(25%) | 1 (25%) | 12 (25%) | 1 |
| Late mortality | 21/82 (26%) | 7 (50%) | 14 (20%) | 0.07 |
| Cumulated long term mortality | 43 (41%) | 13 (65%) | 30 (36%) | 0.01 |
| Relapse and reinfections | 5 (5%) | 1 (6%) | 4 (5%) | 1 |